Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Casma Therapeutics General Information
Casma Therapeutics is advancing its pipeline with a focus on autophagy-based degradation. Recent funding has supported the development of its lead programs, including a degrader for MYD88 mutant tumors.
Contact Information
Drug Pipeline
Pre-clinical
Key Partnerships
Third Rock Ventures, The Column Group, Eventide Asset Management, Schroder Adveq, Amgen Ventures, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, Ono Venture Investment
Casma Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Mar 10, 2026 | $7.6M | Completed | Preclinical |
To view Casma Therapeutics's complete valuation and funding history, request access »